Soligenix (SNGX) Receivables (2010 - 2024)
Soligenix's (SNGX) quarterly Receivables came in at $99650.0 in Q1 2024, down 16.65% YoY from $119552.0 in Q2 2023, and up 283.71% on a QoQ basis from $25970.0 in Q4 2023.
Soligenix (SNGX) Receivables (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 15 years of Receivables data on file, last reported at $99650.0 in Q1 2024.
- Quarterly Receivables fell 16.65% year-over-year to $99650.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $99650.0 (down 16.65% YoY) and the FY2023 annual result came in at -$66122.0, down 127.2% from the prior year.
- Receivables climbed to $99650.0 in Q1 2024, from $25970.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $898218.0 in Q1 2020 to a low of -$165569.0 in Q1 2021.
- A 5-year average of $199662.2 and a median of $127240.0 in 2021 frame the typical range for Receivables.
- Annual changes were most pronounced in 2021 — Receivables sank 118.43% — and 2022, when it jumped 278.59%.
- Tracing SNGX's Receivables over 5 years: stood at $334008.0 in 2020, then tumbled by 52.96% to $157104.0 in 2021, then slumped by 30.19% to $109668.0 in 2022, then tumbled by 76.32% to $25970.0 in 2023, then jumped by 283.71% to $99650.0 in 2024.
- The last three Receivables figures came in at $99650.0 (Q1 2024), $25970.0 (Q4 2023), and $63852.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Soligenix | 6.30 Mn | 6.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 99,650.00 |
| Dec 31, 2023 | 25,970.00 |
| Sep 30, 2023 | 63,852.00 |
| Jun 30, 2023 | 63,284.00 |
| Mar 31, 2023 | 119,552.00 |
| Dec 31, 2022 | 109,668.00 |
| Sep 30, 2022 | 253,742.00 |
| Jun 30, 2022 | 242,017.00 |
| Mar 31, 2022 | 295,692.00 |
| Dec 31, 2021 | 157,104.00 |
| Sep 30, 2021 | 92,326.00 |
| Jun 30, 2021 | 127,240.00 |
| Mar 31, 2021 | -165,569.00 |
| Dec 31, 2020 | 334,008.00 |
| Sep 30, 2020 | 419,320.00 |
| Jun 30, 2020 | 258,183.00 |
| Mar 31, 2020 | 898,218.00 |
| Dec 31, 2019 | 1.46 Mn |
| Sep 30, 2019 | 869,297.00 |
| Jun 30, 2019 | 1.68 Mn |